title: Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?
abstract: The immune-correlate analysis of the RV144 clinical trial revealed that human plasma IgA immune responses elicited by the RV144 vaccine correlated positively with a risk for HIV acquisition. This result once again emphasized that HIV vaccines can potentially have adverse effects leading to enhancement of infection. Here, we discuss previously reported evidence of antibody-dependent enhancement of HIV infection. We also describe how a structure-based epitope-specific sieve-analysis can be employed to mine the molecular mechanism underlying this phenomenon.
authors.affiliation: a Department of Biochemistry and Molecular Pharmacology ; New York University School of Medicine ; New York , NY USA.
authors.forename: Evgeny
authors.initials: E
authors.lastname: Shmelkov
authors.forename: Arthur
authors.initials: A
authors.lastname: Nadas
authors.forename: Timothy
authors.initials: T
authors.lastname: Cardozo
mesh_terms: D016915:AIDS Vaccines / Q000009:adverse effects* / Q000276:immunology; D019067:Antibody-Dependent Enhancement / Q000276:immunology*; D015483:HIV Antibodies / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015658:HIV Infections / Q000276:immunology; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D014611:Vaccination / Q000009:adverse effects*
chemical_list: D016915:AIDS Vaccines; C112734:AIDSVAX; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D007070:Immunoglobulin A
keywords: HIV vaccine; HIV vaccine clinical trials; antibody; antibody epitopes; antibody-dependent enhancement of infection